The short version
- Why people research itA clean, pulsatile GH release for recovery, sleep and body composition.
- What the evidence isPublished human pharmacokinetic work exists on modified GRF (1-29) — this molecule — establishing that it raises GH and IGF-1 in humans and how long it lasts.
- What to watchNumb or tingling hands at night, carpal tunnel from fluid.
How CJC-1295 No Dac works
Short-acting GHRH analog — creates a clean, natural GH pulse without the sustained bleed of the DAC version.
This molecule is Mod GRF (1-29), and its four substitutions are the entire content of the page. The parent is human GHRH(1-29) amide — Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2, the shortest fragment of the 44-residue hormone that retains full activity at the receptor.
Each substitution has one job, and they are not interchangeable.
- Injectable
On the goal map: Lean-mass protection while cutting (Lose fat)
Research on CJC-1295 No Dac5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Published human pharmacokinetic work exists on modified GRF (1-29) — this molecule — establishing that it raises GH and IGF-1 in humans and how long it lasts. No efficacy trial for any body-composition or ageing endpoint.
Correlative data
The GHRH half of the standard stack, used almost universally alongside a ghrelin agonist. Reported experience is of a clean GH pulse with the characteristic flush and slight lightheadedness in the first minutes.
The naming is a persistent source of error in the community: 'CJC-1295 no DAC' and 'modified GRF 1-29' are the same peptide, and it behaves nothing like the DAC version.
How the mechanism reads
A GHRH analog with four amino-acid substitutions that resist enzymatic breakdown, giving a ~30-minute half-life rather than minutes.
MechanisticThat short action is the design, not a limitation. It produces a discrete pulse that mimics physiological GH release and then clears, which is what keeps negative feedback intact — the mechanistic argument for it over the DAC version, which does not.
Mechanistic
Sources
- Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis 2021 · PMID 34665524
- Timms M, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Testing and Analysis 2019 · PMID 30489688
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism 2006 · PMID 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism 2006 · PMID 17018654
CJC-1295 No Dac safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active cancer, since it raises GH and therefore IGF-1.
- Diabetic retinopathy or poorly controlled diabetes, as GH worsens insulin resistance.
- A pituitary tumor or untreated acromegaly features.
- Untreated sleep apnea, which GH-related tissue swelling can worsen.
- Pregnancy, or under 18 with growth plates still open.
What’s expected
- Facial flush, warmth and a head-rush soon after, from the basic peptide charge.
- A short natural GH pulse that fades without a sustained rise.
- Mild water retention and sleep changes.
Watch for
- Numb or tingling hands at night, carpal tunnel from fluid.
- Fasting glucose creeping up.
- Persistent swelling of the face or hands.
Labs that tell you it’s working
- IGF-1: the downstream readout of the pulses, expected to rise modestly.
- Insulin (Fasting): GH counters insulin, so this rises if the axis is too driven.
- HbA1c: the slow glucose consequence of repeated GH pulses.
- Free T3: GH changes peripheral thyroid hormone conversion.
Short-acting GHRH(1-29) analog: pituitary GHRH receptor stimulation gives a physiological GH pulse; harms follow from GH and IGF-1 exposure. PMID 16352683 PMID 17018654
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
CJC-1295 No Dac FAQ4 common questions
- Is CJC-1295 No Dac approved for human use?
- No. CJC-1295 No Dac is a research compound.
- What is CJC-1295 No Dac researched for?
- A clean, pulsatile GH release for recovery, sleep and body composition.
- Which labs show whether it's doing anything?
- IGF-1; Insulin; HbA1c; Free T3: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for CJC-1295 No Dac: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




